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a  b  s  t  r  a  c  t
The  current  suite  of  Food  and  Drug  Administration  (FDA)  approved  antidotes  (i.e., sodium  nitrite,  sodium
thiosulfate,  and hydroxocobalamin)  are  effective  for treating  cyanide  poisoning,  but individually,  each
antidote  has  major  limitations  (e.g.,  large  effective  dosage  or delayed  onset  of  action).  To  mitigate  these
limitations,  next-generation  cyanide  antidotes  are  being  investigated,  including  3-mercaptopyruvate
(3-MP)  and  cobinamide  (Cbi).  Analytical  methods  capable  of  detecting  these  therapeutics  individually
and  simultaneously  (for  combination  therapy)  are  essential  for  the  development  of  3-MP  and  Cbi  as
potential  cyanide  antidotes.  Therefore,  a liquid  chromatography–tandem  mass-spectrometry  method
for the simultaneous  analysis  of  3-MP  and  Cbi  was  developed.  Sample  preparation  of  3-MP  consisted  of
spiking  plasma  with  an  internal  standard  (13C3-3-MP),  precipitation  of plasma  proteins,  and  derivatiz-
ing  3-MP  with  monobromobimane  to produce  3-mercaptopyruvate-bimane.  Preparation  of  Cbi  involved
denaturing  plasma  proteins  with  simultaneous  addition  of  excess  cyanide  to convert  each Cbi  species  to
dicyanocobinamide  (Cbi(CN)2). The  limits  of  detection  for 3-MP  and  Cbi  were  0.5  M  and  0.2 M, respec-
tively.  The  linear  ranges  were  2–500 M for 3-MP  and  0.5–50  M  for Cbi.  The  accuracy  and  precision  for
3-MP  were  100  ±  9%  and <8.3%  relative  standard  deviation  (RSD),  respectively.  For  Cbi(CN)2, the  accuracy
was  100  ±  13%  and  the  precision  was  <9.5%  RSD.  The  method  presented  here  was  used  to  determine  3-MP
and  Cbi  from  treated  animals  and may  ultimately  facilitate  FDA  approval  of these  antidotes  for  treatment
of cyanide  poisoning.
© 2015  Elsevier  B.V.  All  rights  reserved.
1. Introduction
Although the current suite of Food and Drug Administration
(FDA) approved cyanide (HCN and CN−, inclusively represented
as CN) antidotes (i.e., sodium thiosulfate, sodium nitrite, and
hydroxocobalamin (Cbl)) are effective for treating cyanide poison-
ing, each has major limitations [1–3]. Therefore, next generation
cyanide antidotes, are being developed. Two  of these next gen-
eration antidotes, cobinamide (Cbi) and sulfanegen (i.e., dimer
of 3-mercaptopyruvate (3-MP)), have shown promise in remedy-
ing the limitations of currently approved antidotes. For example,
although Cbl (i.e., the current FDA approved direct cyanide bind-
∗ Corresponding author. Fax: +1 605 688 6364.
E-mail address: brian.logue@sdstate.edu (B.A. Logue).
ing treatment [4–6]) works well to detoxify cyanide [7–9], and its
potential adverse effects are generally mild [10,11], it is very large
and can only sequester one CN ion per Cbl molecule. Therefore,
very large doses of Cbl must be administered intravenously over
minutes, making it a poor antidote in mass casualty situations [11].
To address the disadvantages of Cbl, Cbi is being developed as an
alternative direct cyanide binding agent. Cbi is the penultimate pre-
cursor in the biological production of Cbl and is naturally found in
human serum and bile [2,12]. Cbi works by sequestering cyanide
from its active site (i.e., the heme A site in cytochrome C oxidase).
Structurally, Cbi lacks Cbl’s dimethylbenzimidazole ribonucleotide
tail [12,13]. Consequently, it has a smaller mass, greater overall
affinity towards cyanide, (Kf ≈ 1022) [14,15], higher water solubil-
ity, and the ability to bind two  cyanide ions [12,14–17]. Cbi has been
shown to have 3–10 times more potency than hydroxocobalamin,
depending on the formulation [2,18]. The main difference between
http://dx.doi.org/10.1016/j.jchromb.2015.11.027
1570-0232/© 2015 Elsevier B.V. All rights reserved.
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Cbi formulations is the ligand identity, with the current formula-
tion using nitrite ions, to improve absorption during intramuscular
administration [15].
Another treatment strategy for cyanide poisoning is conversion
of cyanide to the much less toxic thiocyanate (SCN−, represented
herein as SCN) with sulfur donors and native sulfurtransferase
enzymes as catalysts. Sodium thiosulfate is currently the only
FDA approved sulfur donor for treating cyanide toxicity. Although
sodium thiosulfate is effective, it has a slow onset of action
attributed to slow entry into cells and the mitochondria [1]. This
necessitates its use in combination with faster acting therapeutics,
typically nitrites. Also, sodium thiosulfate utilizes the enzyme rho-
danese, which is primarily found in the liver and kidneys [19,20],
leaving the heart and central nervous system less protected [19].
Because of the disadvantages of thiosulfate, alternate sulfur
donors are being investigated, including 3-MP [3,16,19]. The con-
version of CN to SCN by 3-MP is catalyzed by 3-MP sulfurtransferase
(3-MST) [3,20,21]. This conversion occurs primarily in blood or tis-
sue areas near blood. The highest concentrations of 3-MST are found
in the liver and kidneys, with heart, brain and lungs also supporting
the enzyme [20,22–24]. In contrast to rhodanese, 3-MST is dis-
tributed in both the cytosol and mitochondria, allowing the reaction
of 3-MP with CN to occur primarily in the cytosol, with the remain-
ing CN distributing into the mitochondria where it is metabolized
by rhodanese. Although 3-MP is an effective sulfur donor, it read-
ily degrades in the blood. Therefore, several prodrugs of 3-MP (i.e.,
chemical compounds that convert to 3-MP upon administration),
inclusively called sulfanegen, were developed. In multiple studies,
intramuscularly administered sulfanegen was highly effective in
reversing cyanide toxicity [3,19,22,25,26].
Although both Cbi and 3-MP have advantages as individual
antidotes, they work by distinct mechanisms. Therefore, the com-
bination of these two compounds has been suggested to provide
greater protection than the compounds alone [16]. In general,
the main advantages of combination therapeutics are (1) low-
ering the dose of the individual components, which potentially
leads to minimized side effects, and (2) allowing drugs with
distinct pharmacokinetic profiles to be administered simultane-
ously, potentially extending the therapeutic window of individual
treatments (e.g., combining a fast-acting quickly metabolized com-
pound with a longer acting therapeutic). As a combination therapy,
Cbi and sulfanegen have been administered intramuscularly to
treat cyanide poisoning in mice [16] with additive protection
against cyanide toxicity.
In order to determine the stability and pharmacokinetic proper-
ties of a 3-MP and Cbi combination therapy, and to ultimately obtain
FDA approval, a validated analytical method is essential. Although
previous analytical methods have been developed to individually
determine 3-MP or various Cbi species [12,27–36], there is a need to
develop an analytical technique to simultaneously determine Cbi
and 3-MP in order to reduce effort, analysis costs, and minimize
necessary sample volumes. Therefore, the focus of this project was
to develop an analytical method to simultaneously determine and
quantify dicyanocobinamide Cbi(CN)2 and 3-MP using LC–MS-MS.
2. Experimental
2.1. Reagents and standards
All solvents were LC–MS grade unless otherwise noted. Ammo-
nium formate and 3-mercaptopyruvate (3-MP; HSCH2COCOOH)
were purchased from Sigma–Aldrich (St. Louis, MO,  USA). Acetone
(HPLC grade, 99.5%) was purchased from Alfa Aesar (Ward Hill, MA,
USA). Cobinamide (C48 H72 CoN11 O8; 989.76 g/mol) was  obtained
from the Department of Medicine, University of California, San
Diego (La Jolla, CA) [17]. Potassium cyanide, sodium hydroxide, and
Millex® tetrafluoropolyethylene syringe filters (0.22 m,  4 mm,
Billerica, MA,  USA) were obtained from Fisher Scientific (Pittsburgh,
PA, USA). Isotopically-labeled 3-MP (HS13CH213CO13COOH) was
synthesized and provided by the Center for Drug Design, University
of Minnesota (Minneapolis, MN,  USA) [3]. Monobromobimane
(MBB, 3-(bromomethyl)-2,5,6-trimethyl-1H,7H-pyrazolo[1,2-
a]pyrazole-1,7-dione; C10H11BrN2O2) was obtained from Fluka
Analytical (Buchs, Switzerland) and a standard solution (500 M)
was prepared in LC–MS grade water and stored at 4 ◦C. 3-MP
calibration and QC standards were prepared from a 3-MP stock
solution (10 mM)  by serial dilution with swine plasma. The internal
standard solution was prepared from a stock solution of 1 mM
isotopically-labeled 3-MP in LC-MS grade water and stored at
4 ◦C. The Cbi(NO2)2 was  prepared by adding excess sodium nitrite
(4:1 NO2−:Cbi(H2O)(OH)+) to ensure two nitrite ligands were
bound to the Cbi [15]. The Cbi(CN)2 was prepared by adding 3x
the concentration of cyanide to Cbi(H2O)(OH)+ in water. Note:
Cyanide is toxic and is released as HCN in neutral and acidic solutions.
Therefore, all solutions were prepared in a well-ventilated hood, and
aqueous standards were prepared in ≥10 mM NaOH.
2.2. Biological fluids
Animal plasma was  obtained from four sources: two  commer-
cial vendors, a study to evaluate the effectiveness of sulfanegen in
rabbits, and a separate study to evaluate Cbi as a cyanide thera-
peutic in rats. Rat plasma (with Na Heparin as an anti-coagulant)
was purchased from Innovative Research (Novi, MI)  and stored at
−80 ◦C until used. Rabbit plasma (EDTA anti-coagulated) and swine
plasma (EDTA anti-coagulated), were purchased from Pel-Freeze
Biological (Rogers, AR, USA) and stored at −80 ◦C until used. Swine
plasma was initially chosen as the method development matrix
because at the time of major development of the analytical method,
Cbi/sulfanegen combination therapy studies were predominantly
carried out in swine. Before the method was  fully validated, animal
models of efficacy testing for Cbi and 3-MP were transitioned to
rats and rabbits, respectively. Therefore, evaluation of the method’s
ability to determine 3-MP and Cbi from treated animals was  car-
ried out from rabbit and rat studies, respectively. Rabbit plasma
from a sulfanegen efficacy study was gathered at SRI International
in Menlo Park, California. The rabbits (New Zealand, 2.2-4.0 kg)
had blood drawn pre-dose. Sulfanegen (136 mg/kg) was  adminis-
tered intramuscularly and blood was drawn at 10 min, 30 min, 1,
2, 4, and 8 h into heparin collection tubes. Plasma was immedi-
ately separated from blood and frozen at −70 ◦C. The samples were
then shipped on dry ice to South Dakota State University for anal-
ysis. Upon arrival, the plasma samples were stored at −80 ◦C until
analyzed.
Rat plasma from a cobinamide/dimethyl trisulfide (DMTS) effi-
cacy study was gathered at the Department of Chemistry at Sam
Houston State University, Huntsville, Texas. Male rats (Charles
River Breeding Laboratories, 315–320 g) had a catheter implanted
on the jugular vein and a DMTS solution (960 L, 50 mg/mL in 15%
Polysorbate 80) was injected into the right leg muscle. Nitrocobi-
namide (43 L, 15 mg/kg) was injected into the left leg muscle.
Blood was  then drawn into heparinized microcentrifuge tubes at 3,
10, 20, 35, and 90 min  after cobinamide administration and plasma
was immediately separated from blood by centrifugation (4 ◦C,
13,500 rpm) for 10 min. Plasma samples were then frozen at −80 ◦C
and shipped on dry ice to South Dakota State University for anal-
ysis. Upon arrival, the plasma samples were stored at −80 ◦C until
analyzed.
All animals were handled in accordance with the Guide for the
Care and Use of Laboratory Animals [37] and accredited by the Asso-
ciation for the Assessment and Accreditation of Laboratory Animal
Care (AAALAC) International. The Institutional Animal Care and
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Use Committee (IACUC) at the respective institution approved the
experiment.
2.3. One-pot sample preparation of total Cbi
Simultaneous analysis of total Cbi and 3-MP was initially
attempted using a one-pot sample preparation method. Total Cbi
was determined by denaturing plasma proteins, converting each
Cbi species to Cbi(CN)2 using excess cyanide and then analyz-
ing the concentration of Cbi(CN)2. Multiple protein denaturing
schemes were evaluated in an attempt to produce quantitative
recovery of Cbi, while not degrading 3-MP, by varying base concen-
tration, cyanide concentration, and temperature. Initially, separate
volumes of swine plasma (in a 2 mL  centrifuge vial) were spiked
with Cbi(CN)2, Cbi(NO2)2, and/or Cbi(H2O)(OH)+ (50 L, 1 mM),  3-
MP (50 L, 1 mM),  and aqueous 3-MP internal standard (100 L,
500 M).  Aqueous potassium cyanide and strong base solutions
(100 L each) were then spiked into the plasma, followed by
vigorous mixing. To convert the Cbi species to Cbi(CN)2, two
concentrations of CN were evaluated, 1.5 mM and 5 mM,  which
correspond to 3× and 10× molar equivalent of cyanide to the high-
est concentration of Cbi calibration standard tested. To denature
plasma proteins and release bound Cbi species, two concentrations
of NaOH (300 M and 1 mM)  were evaluated. When elevated tem-
peratures were investigated for denaturing proteins, samples were
heated on a heat block (VWR International, Radnor, PA, USA) in a
hood at 80 ◦C for 15 min. At the conclusion of all denaturing pro-
tocols, acetone (600 L) was added to precipitate plasma proteins.
Samples were subsequently cold-centrifuged (4 ◦C) for 15 min  at
13,100 RPM (16,500 × g). The supernatant (700 L) was  transferred
to a 4 mL  glass vial and dried under N2.
2.4. Quasi one-pot sample preparation of 3-MP and total Cbi
Because the one-pot sample preparation scheme gave unde-
sired results, a quasi one-pot sample preparation scheme was
devised (i.e., samples were initially split and then recombined for
the duration of sample preparation). To a 2 mL  centrifuge vial,
separate aliquots of 3-MP (50 L in plasma), a 3-MP internal stan-
dard (100 L of 15 M aqueous 3-MP-13C3), and Cbi(CN)2 (50 L
in plasma) were added and mixed. (Note: the addition of Cbi(CN)2
prior to 3-MP internal standard caused 3-MP degradation in pre-
pared samples.) The samples were split evenly (100 L each) into
2 mL  centrifuge vials designated as sub-samples A (i.e., total Cbi
analysis) and B (i.e., 3-MP determination). To sub-sample A, cyanide
(10 mM KCN in 0.1 M NaOH) was added and samples were heated
on a heat block at 80 ◦C for 15 min. While sub-sample A was being
heated, acetone (300 L) was added to sub-sample B to precipitate
proteins. Sub-sample B was then cold-centrifuged (4 ◦C) for 15 min
at 13,100 RPM (16,500 × g) (Thermo Scientific Legend Micro 21R
centrifuge, Waltham, MA,  USA) and placed in the refrigerator. After
sub-sample A was removed from heat, acetone (600 L) was  added
to precipitate plasma proteins and the sample was  centrifuged.
Afterwards, the supernatants (600 L from A, and 300 L from B)
were recombined in a 4 mL  glass vial and dried under N2.
2.5. Sample preparation for LC–MS-MS
For both the one-pot and quasi one-pot sample prepara-
tion schemes, monobromobimane (100 L 500 M) and 5 mM
aqueous ammonium formate with 10% methanol (100 L) were
added to the dried samples. The resulting solution was heated
on a block heater at 70 ◦C for 15 min  to convert 3-MP to a 3-
mercaptopyruvate-bimane (3-MPB) complex [28]. Samples were
filtered with a 0.22 m tetrafluoropolyethylene membrane syringe
filter into autosampler vials fitted with 150 L deactivated glass
inserts for LC–MS-MS analysis. It should be noted that when the
number of samples were above the maximum limit of the sample
apparatus (e.g., the centrifuge), the samples that were not being
actively prepared were stored in a standard refrigerator (4 ◦C) to
impede degradation of 3-MP.
2.6. LC–MS–MS analysis of Cbi(CN)2 and 3-MPB
For LC-ESI-MS–MS analysis a Shimadzu UHPLC (LC 20A
Prominence, Kyoto, Japan) coupled to an electrospray ioniza-
tion quadrupole ion trap QTRAP 5500 LC–MS/MS System (AB
Sciex, Framingham, MA,  USA) was  used. The low-energy colli-
sion dissociation tandem mass spectrometric analysis (CID-MS/MS)
was conducted with the LINAC Collision Cell of the triple
quadrupole/linear ion trap (LIT) instrument. Separation was per-
formed on a Phenomenex Synergy Max  RP column (50 × 2.0 mm,
4 m 80 Å) with an injection volume of 10 L from samples stored
in a cooled autosampler (15 ◦C) and a flow rate of 0.25 mL/min.
Mobile phase solutions consisted of 5 mM aqueous ammonium
formate with 10% methanol (Mobile Phase A) and 5 mM ammo-
nium formate in 90% methanol (Mobile Phase B). A gradient of
0 to 100% B was  applied over 3 min, held constant for 0.5 min,
then reduced to 0% B over 1.5 min. The gradient produced a
total run-time of 5.1 min  and retention times of about 2.60 min
for 3-MPB and 2.9 min  for Cbi(CN)2. The turbo ion-spray inter-
face was heated at 500 ◦C with zero air nebulization at 90 psi in
positive ionization mode with drying and curtain gasses pres-
sures of 60 psi each. The ion-spray voltage, declustering potential,
collision cell exit potential, and channel electron multiplier volt-
age were 4500, 121, 10, and 2600 V, respectively. Low-energy
CID-MS/MS using multiple reaction-monitoring (MRM)  transition
scans of precursor ion → product ion were used for analysis. The
precursor → product ions were 311 → 223.1 and 311 → 192.2 m/z
for 3-MPB and 314 → 223.1 and 314 → 192.2 m/z  for the inter-
nal standard–bimane complex with collision energies of 30.5 and
25 V, respectively. The Cbi(CN)2 transitions of 1015.9 → 930.5 and
1015.9 → 988.5 were utilized with collision energies of 75.91 and
50.70 V and declustering potentials of 249.42 and 237.79 V, respec-
tively. These transitions correspond to a precursor ion of Cbi(CN)+,
which includes both the monocyanocobinamide and dicyanocobi-
namide species [32]. The 1064 m/z transition of Cbi(CN)2 was  not
used because the 1015.9 m/z transition offered greater sensitiv-
ity, lower limits of detection (LODs), and accounts for potentially
incomplete conversion of Cbi species to Cbi(CN)2. The dwell time
was 100 ms  for all transitions. Analyst software (Applied Biosys-
tems version 1.5.2) was used for data acquisition and analysis.
2.7. Calibration, quantification and limit of detection
For validation of the analytical method, we generally followed
the FDA bioanalytical method validation guidelines [38]. The lower
limit of quantification (LLOQ) and upper limit of quantification
(ULOQ) were defined using the following inclusion criteria: (1) cal-
ibrator precision of <15% relative standard deviation (RSD), and (2)
accuracy of ±15% of the nominal calibrator concentration back-
calculated from the calibration curve. It is important to note that
calibration curves must be prepared each day for Cbi(CN)2 because
of daily variation in instrumental sensitivity and sample prepara-
tion with no internal standard to correct for these errors. Calibration
standards were initially prepared from 1 to 1000 M (1, 2, 5, 10,
20, 50, 100, 200, 500, 1000 M)  for 3-MP, with the range later
decreased to 2–500 M.  Calibration curves for Cbi(CN)2 were pre-
pared from 0.5–500 M (0.5, 1, 2, 5, 10, 20, 50, 100, 200, 500 M)
and later decreased to 0.5–50 M.
To determine the accuracy and precision of the method, QCs
(N = 5) were prepared at three concentrations not included in the
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calibration curve: 1.5 and 7.5 M (low QCs for Cbi(CN)2 and 3-MP,
respectively), 7.5 and 30 M (medium QCs for Cbi(CN)2 and 3-MP,
respectively), and 35 and 150 M (high QCs for Cbi(CN)2 and 3-MP,
respectively). The 3-MP internal standard was prepared daily and
added to each sample, calibration standard and QC during sample
preparation. Calibration curves and QCs, were prepared fresh each
day during intra-assay (daily) and inter-assay (over three separate
days, within seven calendar days) analyses to calculate the intra-
assay and inter-assay accuracy and precision.
The LOD was determined by analyzing multiple concentrations
of 3-MP (0.2, 0.5, 1, and 2 M)  and Cbi(CN)2 (0.2, 0.5, 1, 2, 3, 4, and
5 M)  below the LLOQ and determining the lowest concentration
that reproducibly produced a signal-to-noise ratio (S/N) of 3. For
3-MP, noise was measured as the peak-to-peak noise directly adja-
cent to the 3-MP peak since it is inherently present in the plasma of
mammals [20,21]. Cbi(CN)2 is not endogenously present in plasma,
so noise was measured as peak-to-peak noise from blank plasma
over the full elution time of Cbi(CN)2.
2.8. Stability, recovery, and matrix effects
To evaluate the stability of the two analytes, low and high QCs
were stored at various temperatures (room temperature (RT), 4 ◦C,
−30 ◦C, and −80 ◦C) and analyzed at multiple storage times. As sta-
bility samples were prepared for analysis, 3-MP internal standard
was added to help correct for sample preparation and instrumen-
tal variability. The stability of Cbi(CN)2 and 3-MP were calculated
as a percentage of the initial concentration (standards were pre-
pared each day of analysis), with the sample considered stable
if the concentration of the stored sample was within 10% of the
standard. The stability of only Cbi(CN)2 was determined, as the
stability of the other Cbi species of interest (Cbi(H2O)(OH)+ and
Cbi(NO2)2) are well known [15,32]. Long-term stability was  con-
ducted at three storage temperatures (4 ◦C, −30 ◦C, and −80 ◦C).
The samples were analyzed in triplicate after 1, 6, 10, 15, and 30
days. Autosampler stability of 3-MPB and Cbi(CN)2 was  determined
after typical sample preparation of low and high QCs and storage
in a cooled autosampler (15 ◦C) for approximately 2, 4, 8, 12, and
24 h. Short term stability of 3-MP and Cbi(CN)2 was conducted at
RT, after 0, 2, 4, 8, 12, and 24 h. For freeze–thaw stability of 3-MP
and Cbi(CN)2, each set of QCs (low and high) were stored at −80 ◦C
for 24 h, thawed unassisted at RT, and a single set of QCs were pre-
pared and analyzed. The remaining QCs were then placed in the
−80 ◦C freezer. This procedure was repeated for a total of three
freeze–thaw cycles. A set of QC standards (low and high) for 3-MP
and Cbi were prepared fresh each day. Stability was determined by
comparing QCs to standards.
To determine the recovery of Cbi(CN)2 and 3-MP, five aque-
ous QCs (low, medium, and high) were prepared, analyzed and
compared with equivalent concentrations of QCs in plasma. Recov-
ery was calculated as a percentage by dividing the analyte plasma
concentration with the calculated aqueous equivalent QC concen-
tration. Matrix effects were evaluated by comparing aqueous and
plasma calibration curves.
3. Results and discussion
3.1. Determination of Cbi(CN)2 and 3-MP from swine plasma
Multiple species of Cbi are likely to exist in plasma samples
after its administration. For example, if the current formula-
tion of Cbi(NO2)2 [15] is administered intramuscularly to a
victim of cyanide poisoning, Cbi(NO2)2, Cbi(CN)2, Cbi(CN)(NO2),
Cbi(H2O)(OH)+, Cbi(CN)(OH), and other Cbi species may  be present.
Therefore, in order to determine the total Cbi in a plasma sam-
Fig. 1. Various attempts to fully convert Cbi species (Cbi(H2O)(OH)+) and Cbi(NO2)2)
to  Cbi(CN)2, while monitoring 3-MP stability. The use of 1.5 or 5 mM CN and base
(10  mM)  with or without heat (80 ◦C) to denature plasma proteins did not fully
convert Cbi(H2O)(OH)+ to Cbi(CN)2. The use of 5 mM CN with base (100 mM)  and
heat  (80 ◦C) fully converted all Cbi species to Cbi(CN)2 but degraded 3-MP. The quasi
one-pot method allowed full conversion of Cbi species to Cbi(CN)2 and protection
of  the 3-MP.
ple, all Cbi species were converted to Cbi(CN)2 by the addition of
excess cyanide [18,32,39]. This approach is based on the strong
affinity cyanide has for the cobalt atom of Cbi, allowing cyanide to
out-compete other Cbi ligands and create one form of cobinamide.
Once all the Cbi species are converted to Cbi(CN)2, the total Cbi
can be analyzed as Cbi(CN)2. Another difficulty in analyzing Cbi is
its affinity for haptocorrin proteins [2,32]. Because it is necessary
to precipitate plasma proteins during analysis, any protein-bound
Cbi would decrease the amount of free Cbi available for analysis,
consequently decreasing recovery. Therefore, it was necessary to
denature the plasma proteins to release bound Cbi. Denaturing
the plasma proteins was  accomplished using the combination of
base and heat. Simultaneously, CN was  used to convert Cbi species
to Cbi(CN)2, which has the added advantage of lower affinity for
plasma proteins than other Cbi species [18]. Others have used this
approach successfully to analyze total Cbi from plasma spectropho-
tometrically [18].
It is known that 3-MP degrades quickly in plasma at room tem-
perature [28], so it was inferred that it would be highly unstable
when denaturing proteins at elevated temperatures. Therefore,
no heat was used to denature proteins when initially converting
Cbi species to Cbi(CN)2 with excess cyanide. Two concentrations
of cyanide were evaluated, 1.5 and 5 mM (i.e., 3× and 10× the
highest concentration Cbi(CN)2 calibration standard tested) under
mildly basic conditions (10 mM NaOH). As shown in Fig. 1, the
use of 1.5 and 5 mM cyanide produced ∼70% and ∼100% con-
version Cbi(NO2)2, respectively. Although 100% of the Cbi(NO2)2
was converted to Cbi(CN)2 using 5 mM CN, only about 30% of
the Cbi(H2O)(OH)+ was  converted to Cbi(CN)2 at both CN concen-
trations tested. Although it was expected that excess CN would
degrade 3-MP, it was  found that 3-MP signals remained consis-
tently 100 ± 10%. This may  be due to the rapid reactivity of CN with
Cbi and multiple other components of blood, inclusively minimiz-
ing the reaction of CN with free 3-MP.
The inability to fully convert Cbi(H2O)(OH)+ to Cbi(CN)2 under
ambient temperatures indicated that the conditions were too mild
to fully release the Cbi(H2O)(OH)+ from plasma proteins. Therefore,
a harsher denaturing protocol was added to the sample prepa-
ration procedure, where both higher concentrations of base and
elevated temperatures were evaluated. Fig. 1 shows that 5 mM
KCN, a higher concentration of base (0.1 M NaOH), and heating at
80 ◦C converted both Cbi(NO2)2 and Cbi(H2O)(OH)+ completely to
Cbi(CN)2 (100 ± 10%). However, as expected, 3-MP was  not stable
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at this temperature. Since the conditions to prepare 3-MP and Cbi
were not fully compatible, we evaluated a quasi one-pot sample
preparation procedure.
For the quasi one-pot procedure, the samples were initially
split in half and prepared separately until precipitation of pro-
teins occurred, then the prepared samples were re-combined for
the duration of the analysis. As shown in Fig. 1, full conversion of
Cbi to Cbi(CN)2 was successful and 3-MP was stable with the quasi
one-pot procedure. Therefore, the quasi one-pot sample prepara-
tion scheme was adopted for plasma sample preparation in order
to analyze 3-MP and Cbi(CN)2 simultaneously.
Utilizing the quasi one-pot sample preparation, Fig. 2 shows the
chromatograms of 3-MP (A) and Cbi(CN)2 (B), eluting at 2.6 and
2.9 min, respectively. Fig. 2A shows four 3-MP chromatograms that
are plotted from samples prepared with multiple Cbi species. Each
is essentially identical, indicating the presence of the Cbi species
do not interfere with the analysis of 3-MP. Fig. 2B, shows chro-
matograms of Cbi(CN)2 after conversion from Cbi(H2O)(OH)+ and
Cbi(NO2)2, each in the presence of 3-MP. The chromatograms are
essentially identical to the Cbi(CN)2 standard, indicating that full
conversion of Cbi(H2O)(OH)+ and Cbi(NO2)2 was accomplished, and
that 3-MP does not interfere with Cbi analysis. The final combined
3-MP/Cbi method shows excellent selectivity with no interfering
peaks observed in the blank. In fact, in swine plasma, no other peaks
were observable for either 3-MPB or Cbi(CN)2.
3.2. Linear range, limit of detection, and sensitivity
The linear range, limit of detection, and sensitivity of the method
were evaluated to ensure the applicability of the method for
combined 3-MP and Cbi analysis. The linear range for 3-MP was
2–500 M using a 1/x2 weighted curve. Of the original concentra-
tions tested, 1 and 1000 M were excluded because they did not
meet the accuracy and/or precision inclusion criteria. The linear
range of the current method for 3-MP was actually greater than
our previous study, where we analyzed 3-MP individually [28].
The linear dynamic range for Cbi(CN)2 was 0.5–50 M using a 1/x2
weighted calibration curve. Cbi calibrators at concentrations of 100,
200, and 500 M were excluded because they did not meet the
accuracy and/or precision inclusion criteria.
The LODs of Cbi(CN)2 and 3-MP were 0.2 M and 0.5 M,  respec-
tively. The LOD of 3-MP was similar to our previous analysis of 3-MP
alone, 0.1 M [28], but was significantly higher than the 1 nM LOD
found for an HPLC method with fluorescence detection [27] uti-
lized by Ogasawara et al. The LOD for Cbi(CN)2 was also higher
than a spectrophotometric method reported by Ma et al., which
generated a LOD of 30 nM [31]. Although the LODs for the method
reported here were higher than both the HPLC and spectropho-
tometric methods, they are acceptable for translational studies of
3-MP and Cbi, because plasma concentrations of 3-MP and Cbi from
treated animals and humans are expected to be well above 1 M
[15,19,25,26,28].
The LLOQs for 3-MP and for Cbi(CN)2 were 2 M and 0.5 M,
respectively. The ULOQs were 500 M for 3-MP and 50 M for
Cbi(CN)2. Boss et al. reported a ULOQ of 10 M with a linear range
of 2.5 orders of magnitude. Ogasawara et al. reported a linear range
from 0.2 to 40 M for 3-MP, and our LC–MS-MS previous method
for 3-MP alone had a linear range from 0.5 to 100 M.  Similar to
the LODs, although previous methods had lower linear ranges, our
linear range covers at least 2 orders of magnitude and should be
very useful with therapeutic studies where large concentrations
are administered.
3.3. Accuracy and precision
Accuracy and precision were determined by quintuplicate anal-
ysis of low, medium, and high QCs (7.5, 30, and 150 M for 3-MP
and 1.5, 7.5 and 35 M for Cbi(CN)2) on three different days (within
7 calendar days; Table 1). The intra-assay accuracy and precision
for 3-MP were 100 ± 9% and <5.5% RSD, respectively. For Cbi(CN)2,
the intra-assay accuracy was  100 ± 13% and the intra-assay preci-
sion was  <9% RSD. The inter-assay accuracy for 3-MP was 100 ± 9%
and 100 ± 10% for Cbi(CN)2. The inter-assay precision for 3-MP was
<8.5% and <9.5% for Cbi(CN)2. 3-MP had better accuracy and pre-
cision due to the internal standard that could correct for daily
instrumental variations. Even without an internal standard for
Cbi(CN)2, the precision and accuracy for the method were excel-
lent and well within the FDA method validation guidelines for both
analytes.
Our previous method for 3-MP analysis produced an accuracy
and precision of 100 ± 9% and <7% RSD, respectively, in aggregate
(both intra and inter assay values are included) [28]. Ogasawara
et al. [27] reported a better precision of <4.8%, but no accuracy
was presented. The precision for the analysis of total cobinamide
using the Ma  et al. multiwavelength spectrometry method was sim-
ilar, <7.6% for all QCs [31]. The likely cause of the slightly worse
precision for our method compared to other similar methods for
single species, is differences in the instruments used and the more
involved sample preparation requirements for the simultaneous
analysis of 3-MP and Cbi.
3.4. Stability, recovery, and matrix effects
The long term stability of Cbi(CN)2 and 3-MP in swine plasma
(i.e., both Cbi(CN)2 and 3-MP were added to each plasma sample
for stability studies) was  evaluated at 4, −30, and −80 ◦C, with
short-term stability evaluated at room temperature for 24 h. The
low and high 3-MP QCs were stable at −80 ◦C for at least 30 days,
but both degraded rapidly at 4 ◦C. While the high 3-MP QC  was
stable at −30 ◦C for at least 30 days, the low QC was only stable
for 6 days. Cbi(CN)2 was extremely stable, with the low and high
Cbi(CN)2 QCs stable for at least 30 days under each long-term stor-
age condition. For freeze–thaw stability, 3-MP and Cbi(CN)2 were
both stable for all three cycles. This result differs from our previous
3-MP analysis, where 3-MP was only stable for one freeze–thaw
cycle [28]. To determine if Cbi had a stabilizing effect on 3-MP dur-
ing freeze–thaw cycles, freeze–thaw stability was  evaluated with
3-MP alone. The 3-MP was still stable for 3 freeze–thaw cycles,
indicating that Cbi(CN)2 did not affect the 3-MP stability. In our
previous method, although 3-MP was  reported as stable for only
one freeze–thaw cycle (i.e., within 90% of the initial analysis), it was
within 80% of the initial analysis for all three days [28]. Therefore,
it is likely that improved sample preparation and handling during
the current study increased the stability of 3-MP for the second
and third freeze–thaw cycles. For short-term stability (at RT), 3-MP
was stable for less than 4 h for both the high and low QCs. The 3-MP
was again more stable than in our previous work [28]. The Cbi(CN)2
was extremely stable at RT, with concentrations for both QCs within
±10% for the entire study. In the autosampler, both the prepared
3-MP, as 3-MPB, and Cbi(CN)2 were found stable for at least 24 h.
The results from the stability studies, suggest that if storage is nec-
essary, plasma samples with 3-MP and Cbi(CN)2 should be frozen
and immediately stored at −80 ◦C. Once samples are thawed, they
should be prepared immediately and refrozen if future analysis is
necessary. Samples can also be stored on a cooled autosampler for
at least 24 h after preparation.
The recovery of 3-MP for the low, medium and high QCs
were 104%, 99% and 99%, respectively, and no matrix effects were
observed for 3-MP. Recoveries of 3-MP in previous methods were
186 M.W. Stutelberg et al. / J. Chromatogr. B 1008 (2016) 181–188
Fig. 2. LC–MS-MS analysis of 3-MP and Cbi(CN)2 analytes in swine plasma. (A) The chromatograms (MRM 311 → 223 m/z) represent the signal response of 3-MP, eluting at
2.65  min, prepared from plasma with varying Cbi species and excess cyanide. (B) Chromatograms of multiple species of Cbi with 3-MP and excess cyanide after conversion
to  Cbi(CN)2. The Cbi(CN)2 elutes at 2.91 min. The chromatograms represent the signal response of the MRM  transition of 1015.9 → 930.5 m/z.
Table 1
The accuracy and precision of 3-mercaptopyruvate and Cbi(CN)2 analysis spiked in swine plasma by LC–MS-MS.
Analyte Concentration (M) Intra-assay accuracya (%) Intra-assay precisiona (%RSD) Inter-assay accuracyb (%) Inter-assay precisionb (%RSD)
3-
MP
7.5 100 ± 4 5.24 100 ± 5 8.22
30  100 ± 9 2.57 100 ± 9 5.83
150  100 ± 5 5.12 100 ± 6 8.34
Cbi(CN)2 1.5 100 ± 7 7.96 100 ± 10 8.43
7.5  100 ± 10 2.73 100 ± 9 9.47
35  100 ± 13 8.99 100 ± 7 6.48
a QC method validation (N = 5) for day 1.
b QC mean from three different days of method validation (N = 15).
75–81% [28] and 79–85% [27]. Again, improved sample handling is
likely the reason for improved 3-MP recoveries in this study. The
apparent initial recoveries for Cbi(CN)2 were 29%, 29%, and 33%
for the low, medium, and high QCs, respectively. The recoveries
were highly reproducible both with and without 3-MP. To deter-
mine if the apparently low recoveries for Cbi were truly due to low
recovery or due to matrix effects, calibration curves for Cbi(CN)2
were produced in aqueous solution and in plasma. The slope of the
Cbi(CN)2 plasma calibration curve was 2–3 times less than the slope
of the aqueous calibration curve, clearly indicating matrix effects
were present for Cbi(CN)2 analysis from plasma. Therefore, one-half
to one-third of the aqueous signal is produced when the plasma
matrix is present. In aggregate the extent of the matrix effects,
results from the stability studies, and the ability to fully convert
all Cbi species to Cbi(CN)2 (Fig. 1), indicates that the apparently
low recovery was  caused by matrix effects. Because an internal
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Fig. 3. (A) The LC–MS-MS chromatograms from sulfanegen treated rabbits compared to 3-MP spiked rabbit and swine plasma, and blank plasma with all 3-MP samples
eluting  at 2.65 min. (B) Cbi treated rats compared to spiked Cbi(CN)2 swine and rat plasma and blank plasma, with Cbi(CN)2 eluting at 2.9 min. Treated rats with Cbi and
spiked  plasma have the same retention time of Cbi(CN)2. Non-spiked and spiked 3-MP or Cbi(CN)2 swine can be seen in Fig. 2.
standard for Cbi(CN)2 would likely correct for matrix effects, the
addition of an internal standard for Cbi(CN)2 may  be an area of
further improvement of the method.
3.5. Analysis of Cbi and sulfanegen-exposed animals
The validated LC–MS-MS method was applied to the analysis
of plasma gathered from rabbits and rats treated with sulfanegen
and cobinamide, respectively. The LC–MS-MS analysis of sulfane-
gen treated rabbit and Cbi treated rat plasma is shown in Fig. 3.
The sulfanegen treated rabbit plasma contains greatly elevated
3-MP concentrations compared to untreated rabbits. Unlike 3-
MP swine samples, another peak was observed in rabbit plasma
(eluting at 3.15 min), but was fully resolved from the 3-MP peak
(Rs = 1.91). Similarly, elevated Cbi concentrations were observed
with Cbi treated compared to untreated rats. Overall, Fig. 3 con-
firms that the validated method has the ability to detect 3-MP
and Cbi in the plasma of sulfanegen and cobinamide treated ani-
mals. In the near future, a pharmacokinetic study that utilizes
sulfanegen and Cbi as a combination therapeutic for cyanide poi-
soning will be performed using the LC–MS-MS method presented
here.
4. Conclusion
An LC–MS-MS method for the simultaneous detection of
Cbi(CN)2 and 3-MP was  developed featuring simple sample prepa-
ration, rapid analysis, excellent accuracy and precision, excellent
limits of detection, and linear ranges of at least 2 orders of magni-
tude. The method presented here has the ability to simultaneously
analyze 3-MP and Cbi from the plasma of treated animals, which
will facilitate the study of sulfanegen and Cbi as a combination
therapy for cyanide poisoning.
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